| Screening for diabetes. | |
| | |
MedLine Citation:
|
PMID: 22228253 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
SUMMARY: The prevalence of type 2 diabetes is rapidly increasing. A strong rationale exists for identifying asymptomatic individuals who are at high risk or are likely to have diabetes. Screening programs may provide a conduit through which diabetes intervention may be targeted towards those who might benefit most. Diabetes screening could lessen disease burden in two ways. Firstly, by identifying people with undiagnosed diabetes, the burden of diabetes complications could be lessened through appropriate management of the condition. Secondly, by indentifying people at high risk of developing diabetes, and entering these people into diabetes prevention programs, the number of people with diabetes could be reduced. Screening for diabetes should ideally involve a non-invasive risk assessment followed by blood testing for those found to be at high risk. It should be noted that conclusive randomised controlled trial data to support the long-term health and economic impact of screening programs is lacking. The answers surrounding who and how we should screen for diabetes and the associated long term benefits will continue to evolve as the evidence base builds. As the use of screening for diabetes builds in popularity, it is essential that health care systems are sufficiently equipped to effectively manage the newly identified high risk and prevalent cases of type 2 diabetes. |
| | |
Authors:
|
K Backholer; L Chen; J Shaw |
Related Documents
:
|
12415563 - Effects of cod liver oil on tissue antioxidant pathways in normal and streptozotocin-di... 10799703 - Oxidative stress and hne conjugation of glut3 are increased in the hippocampus of diabe... 11692183 - Genetic variability of the sur1 promoter in relation to beta-cell function and type ii ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-5 |
Journal Detail:
|
Title: Pathology Volume: - ISSN: 1465-3931 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0175411 Medline TA: Pathology Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
*Baker IDI Heart and Diabetes Institute, Melbourne †Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The NEXUS criteria: do they stand the test of time?
Next Document: Screening for familial hypercholesterolaemia.